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S U M M A R Y
Human African trypanosomiasis (HAT) is caused by sub-species of the parasitic protozoan Trypanosoma
brucei and is transmitted by tsetse ﬂies, both of which are endemic only to sub-Saharan Africa. Several
cases have been reported in non-endemic areas, such as North America and Europe, due to travelers, ex-
patriots or military personnel returning from abroad or due to immigrants from endemic areas. In this
paper, non-endemic cases reported over the past 20 years are reviewed; a total of 68 cases are reported,
19 cases of Trypanosoma brucei gambiense HAT and 49 cases of Trypanosoma brucei rhodesiense HAT.
Patients ranged in age from 19 months to 72 years and all but two patients survived. Physicians in non-
endemic areas should be aware of the signs and symptoms of this disease, as well as methods of
diagnosis and treatment, especially as travel to HAT endemic areas increases. We recommend extension
of the current surveillance systems such as TropNetEurop and maintaining and promotion of existing
reference centers of diagnostics and expertise. Important contact information is also included, should
physicians require assistance in diagnosing or treating HAT.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is endemic to sub-Saharan Africa where it is a major
threat to public health in 36 countries.1 It is caused by Trypanosoma
brucei, a single-celled eukaryotic parasite and member of the
Kinetoplastida order.2 Two subspecies are able to infect humans:
Trypanosoma brucei gambiense causes a chronic form of HAT in
West and Central Africa, while Trypanosoma brucei rhodesiense is
the pathogenic agent for the more acute form of the disease and is
endemic to Eastern Africa.2,3 The parasite is transmitted by the bite
of an infected tsetse ﬂy (genus Glossina), and cases of HAT are only
found in areas of tsetse ﬂy infestation, which are limited to sub-
Saharan Africa. However with the increased movement of people,
some travelers, military personnel and immigrants have been
reported as HAT-positive. Here, the non-endemic cases of HAT are
reported, as well as their frequency and outcome; laboratory* Corresponding author. Tel.: +31 20 566 2318; fax: +31 20 697 1841.
E-mail address: e.adams@kit.nl (E.R. Adams).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.018infections with T. brucei are considered outside the scope of this
review.
The Trypanosoma parasites are transmitted through the bite of
an infected tsetse ﬂy,4 and undergo complex changes during their
life-cycle alternating between the insect vector and the mammal
host. After the parasites are inoculated into man, they proliferate at
the infection site, causing an inﬂammatory nodule or ulcer, also
known as a trypanosomal chancre; it is typically described as a
circumscribed, red, indurated nodule.5 Previous studies have
shown that the ulcer is much more commonly seen in patients
suffering from T. b. rhodesiense HAT, with lesions in 70–90% of cases
appearing 5–10 days after being bitten by the infected tsetse ﬂy;
this is around the same time as fever and detectable parasitemia in
the blood.6 Chancres are rarely seen in T. b. gambiense infections,
possibly because most infections are detected after the chancre has
disappeared.7
HAT can be classiﬁed into two clinical stages, depending on
whether parasites have crossed the blood–brain barrier (BBB) into
the central nervous system.3 After inoculation, trypomastigotes
spread via lymph into diverse peripheral tissues and organs
initiating the hemolymphatic stage.8 Diverse clinical symptoms,
mostly reﬂecting inﬂammatory reactions, may appear, of whichses. Published by Elsevier Ltd. All rights reserved.
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European patients develop a rash on the torso and most patients
will have swollen, palpable lymph nodes.9 Patients suffering from
T. b. gambiense HAT will often show lymphadenopathy, usually on
the back of the neck, a condition known as Winterbottom’s sign.
Parasites can, at this stage, be microscopically detected in blood
and lymph node aspirates depending on parasite number.
Signs and symptoms may subside after the acute ﬁrst stage. In
the second stage, also known as the meningo-encephalitic stage,
parasites enter the central nervous system.8 This process occurs
within weeks for T. b. rhodesiense or months or years after initial
infection by T. b. gambiense. As the disease progresses, the classical
signs of late-stage HAT become apparent:8 severe headaches, a
disruption of the circadian rhythm, with night-time insomnia and
daytime somnolence; altered mental functions and personality
changes may arise while generalized meningo-encephalitis can
lead to coma and death.4 Other symptoms including anorexia,
altered endocrine functions,10 demyelination and leuko-encepha-
litis are also typical.11 It is important to note that not all patients
will show the same signs and symptoms of HAT.
2. Diagnosis and treatment
Deﬁnitive diagnosis relies upon microscopy, however parasite
numbers of less than 100 trypanosomes/ml can be difﬁcult to
detect with microscopy alone.7 Concentration methods such as
microhematocrit centrifugation,12 quantitative buffy-coat analy-
sis,13 or mini-anion exchange columns14 can be used to concen-
trate the parasites for easier microscopic detection. In West Africa,
many endemic screening programs rely on the card-agglutination
test for trypanosomiasis (CATT). The CATT is based on the
antibody-mediated agglutination of ﬁxed trypanosomes carrying
particular surface glycoproteins and is a sensitive assay to detect T.
b. gambiense-speciﬁc antibodies in blood.15 T. b. rhodesiense lacks
these particular surface glycoproteins and thus CATT is not
appropriate for the diagnosis of T. b. rhodesiense HAT.16 Patients
with T. b. gambiense HAT are at risk of misdiagnosis with other
infections due to cross-reacting antibodies against Toxoplasma
gondii, Strongyloides stercoralis,17 Epstein–Barr virus (EBV),18
cytomegalovirus (CMV),19 Plasmodium ﬁeldi, Plasmodium brasilia-
num, and Borrelia burgdorferi.20 Molecular techniques, such as
polymerase chain reaction (PCR), loop-mediated ampliﬁcation
(LAMP) and nucleic acid sequence-based ampliﬁcation (NASBA)
have been developed and evaluated; however, they have yet to be
adopted or validated for use in the clinical setting.4,7,21–23
To diagnose second-stage HAT, trypanosomes must be micro-
scopically detected in the cerebrospinal ﬂuid (CSF).24 An elevated
(>5  106/l) number of white blood cells in the CSF is also used to
deﬁne the second stage of the disease; however this cut-off is
sometimes debated.8
There are only ﬁve licensed drugs for the treatment of HAT.25
Pentamidine and suramin are available to treat the disease before
parasites invade the central nervous system; pentamidine is the
recommended drug in the treatment of ﬁrst-stage T. b. gambiense
HAT, and suramin is recommended for ﬁrst-stage T. b. rhodesiense
HAT.8 To treat second-stage HAT, drugs that cross the BBB are
essential.4 Melarsoprol is the only drug available to treat T. b.
rhodesiense-caused HAT and is the most economical,26 while T. b.
gambiense HAT can also be cured with eﬂornithine or a
combination of eﬂornithine and nifurtimox.27 Melarsoprol is an
organo-arsenic compound that causes frequent adverse reactions,
which can be severe and even life-threatening. While a compre-
hensive review on the treatment of HAT is available in Brun et al.
2010,8 we have included some important contact information for
assistance in the diagnosis and treatment at the end of this review.3. Non-endemic clinical cases from the literature
A recent search of PubMed and ProMED-mail, as well as
personal communication, resulted in 68 reported cases of HAT in
non-endemic countries. Of these, 57 cases were found through a
PubMed search (search terms: ‘trypanosoma OR HAT OR African
trypanosomiasis OR sleeping sickness NOT Chagas NOT animal
NOT reservoir’) and through a bibliographic search of articles. The
search was limited to the past 20 years (1990–2010). Three cases,
all related, were found by personal communication (P. Bu¨scher).28
A ProMED-mail search using ‘trypanosomiasis’ dating back to 1994
returned 184 reports, however there were only eight additional
human cases. Many of these cases were also reported on
TropNetEurop (http://www.tropnet.net/special_reports/tryps_ex_
serengeti.pdf), a European surveillance network for imported
infectious diseases.
4. Non-endemic West African trypanosomiasis
Nineteen cases of non-endemic T. b. gambiense HAT were found
in the literature search (Table 1). Most of the cases were either
immigrants (6/19, 32%) from endemic regions who had migrated to
Europe, Australia or North America,17,19,29,30 or ex-patriots (8/19,
42%) who had been stationed in endemic regions;18,31–35 the
remaining cases were unspeciﬁed (5/19, 26%). All described T. b.
gambiense HAT cases were diagnosed after a considerable time had
elapsed after the infection, which is typical for the chronic form.8
Of the 19 cases of T. b. gambiense HAT, nine cases were diagnosed in
the ﬁrst stage of the disease, eight were diagnosed in the second,
and two were not speciﬁed,28 but all were successfully treated.
Here we discuss selected cases that highlight important observa-
tions.
A New Zealand man had been posted in Nigeria and Gabon and
was treated in the UK.31 He was initially diagnosed with and
treated for loa loa and schistosomiasis; however splenomegaly,
lymphadenopathy, and elevated IgM levels persisted. Trypanoso-
miasis was suspected, but the positive diagnosis for HAT requires
the detection of parasites. Initial examination of lymph, blood, and
marrow failed to detect any parasites. Two months after his initial
presentation, he returned and trypanosomes were detected in a
blood smear and lymph node aspirates. These were presumed to be
T. b. gambiense given the patient’s history. He was treated and
cured with suramin and diﬂuoromethylornithine. Individually,
these parasitic infections are rarely seen in non-endemic regions;
for one patient to be diagnosed with all three seems ‘‘most
improbable’’ (Scott, 1991).31 It is important to remember that
travelers to endemic regions may be exposed to many possible
parasitic infections. Although one disease may be diagnosed,
physicians should consider other possible infections, especially if
atypical symptoms are present.
Three cases of T. b. gambiense HAT encountered in Portugal may
be examples of unusual transmission of the disease.28 A 30-year-
old woman, who had never traveled to an endemic HAT region, was
admitted to hospital in Portugal with lesions on her thighs,
weakness, and pain. She was clinically and serologically diagnosed
with Lyme disease. Fever, leukopenia, and anemia developed,
which led to the microscopic examination of tissues, including CSF,
where trypanosomes were detected. Both CATT and PCR were
positive and indicated infection with T. b. gambiense. The patient
was treated with eﬂornithine and was reported to be healthy 3
years later. While determining the route of transmission, it was
discovered that her companion, a Brazilian man who had traveled
to Angola for a military mission, was an asymptomatic carrier and
he was subsequently treated. Sexual transmission was proposed,
although sharing of needles during drug abuse cannot be excluded
(P. Bu¨scher, personal communication). Furthermore, the woman’s
Table 1
Reported non-endemic cases of Trypanosoma brucei gambiense human African trypanosomiasis
Age Sex Nationality Country of
exposure
Year Clinical features/symptoms Diagnosis Stage Treatment Outcome Ref.
32 M New Zealander (ex-pat) Nigeria, Gabon 1991 Lesion, rash, fever, lymphadenopathy,
splenomegaly, elevated levels of IgM
Lymph, blood I Suramin, diﬂuoromethyl-
ornithine
Positive 31
Young M French
(immigrant from Angola)
Angola 1992 Fever, insomnia, elevated levels of
IgG and IgM
ND II Eﬂornithine ND 19
52 F Dutch (immigrant from
Cameroon)
Cameroon 1995 Rash (neck, shoulders), elevated IgM CSF II Suramin, melarsoprol Positive 29
32 M Italian (ND) Zaire 1996 Fever, malaise Blood I Eﬂornithine Positive 46
45 M French (ex-pat) Gabon 1999 Lesion, fever, elevated IgM Blood I Pentamidine Positive 32
ND M French (ex-pat) Guinea 2000 Weakness, sweats, vomiting, myalgia,
weight loss, splenomegaly, fever,
elevated IgG and IgM, lesion
CSF, blood II Eﬂornithine Positive 18
53 M French (ex-pat) Guinea 2000 Lesion, chills, weakness, fever,
lymphadenopathy, hepatosplenomegaly,
elevated IgG and IgM
Blood I Pentamidine Positive 33
30 F Portuguese Portugal 2001 Lesion, weakness, fever, leukopenia, anemia Marrow, blood,
CSF, CATT, PCR
II Eﬂornithine Positive 28
19 mo M Portuguese Portugal 2001 Vertical transmission ND ND ND Positive 28
ND M Brazilian (military) Angola 2001 Asymptomatic carrier ND ND ND Positive 28
42 M Canadian (immigrant
from Zaire)
Zaire 2002 Insomnia, anorexia, fatigue, headaches,
lymphadenopathy, elevated IgM, fever
Blood, CSF II Eﬂornithine Positive 17
44 M Italian (ND) Gabon 2005 Fever, headache, weakness, anorexia,
lymphadenopathy, hepatosplenomegaly
Blood, CSF II Eﬂornithine ND 35, 36
54 F Italian (ND) Central African
Republic
2005 Fever, headache, insomnia, fatigue,
splenomegaly
Blood I Pentamidine,
eﬂornithine
Positive 35, 36
37 M French (ex-pat) Gabon 2007 Fever, fatigue, anorexia, headache, insomnia,
rash, lymphadenopathies
Blood, lymph I Pentamidine Positive 34, 35
72 M French (ex-pat) Gabon 2007 Pruritus, fever, weakness, anorexia,
lymphadenopathy, elevated IgG and IgM
Blood I Pentamidine Positive 34, 35
19 F Australian
(immigrant from
Sudan)
Uganda 2008 Lethargy, fever, seizures, cachexia, pruritus,
elevated IgG and IgM, encephalopathy
CSF II Eﬂornithine Positive 37
50 M French (ex-pat) Gabon 2009 Fever, fatigue, lesion, lymphadenopathy Blood I Pentamidine Positive 38, 3
27 F Dutch (immigrant
from Angola)
Angola 2009 Fatigue, insomnia, anorexia, depression, coma CSF II Eﬂornithine Positive 30, 39
24 F Australian (immigrant
from Sudan)
Uganda 2009 Fever, weight loss, seizures, headaches,
lymphadenopathy, somnolence
Brain biopsy II Pentamidine,
eﬂornithine
Positive 40
M, male; F, female; ND, no data mentioned; CSF, cerebrospinal ﬂuid; CATT, card-agglutination test for trypanosomiasis; PCR, polymerase chain reaction.
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sickness, likely due to vertical transmission, and was successfully
treated.
Bisofﬁ et al. (2005) reported an Italian patient who had reported
feeling unwell for over 6 months before seeking treatment. He was
diagnosed with second-stage T. b. gambiense HAT and eﬂornithine
was requested from the World Health Organization (WHO). The
treatment was sent by the WHO, but was subsequently delayed by
9 days while it was held at Italian customs.36 The patient’s
symptoms abated once eﬂornithine treatment was started. While
it is unlikely that a 9-day delay caused any signiﬁcant damage, this
case does highlight the importance of having timely access to the
required pharmaceutical treatment. Had the patient been suffering
from the more acute T. b. rhodesiense HAT, it is likely that this 9-day
delay could have had severe ramiﬁcations, including coma or even
death.
In one particular case seen in France,18 a patient was incorrectly
diagnosed with EBV based on antibody detection; in this case the
misdiagnosis was due to cross-reactivity. Upon ﬁrst admission to
the hospital, no trypanosomes were detected in the blood. The
correct diagnosis of T. b. gambiense HAT was not obtained until
after emergency hospitalization 6 months later. During the second
admission, microscopy of a blood smear and CSF showed
trypanosomes. The patient was successfully treated with eﬂor-
nithine. Physicians should be aware of possible cross-reactions
when performing antibody testing.
5. Non-endemic East African trypanosomiasis
East African trypanosomiasis is distributed throughout eastern
and south-eastern Africa, an area receiving an increasing number
of tourists due to the popularity of game reserves.35 T. b.
rhodesiense HAT presents more frequently as an acute disease;
death can occur less than 2 weeks after infection.41 The most
typical signs are the trypanosomal chancre at the site of the tsetse
ﬂy bite and high fever. Forty-nine cases of non-endemic T. b.
rhodesiense HAT were encountered in the literature search (Table
2). While most of the cases were tourists (34/49, 69%), three of the
cases were soldiers (6%) who had been stationed in endemic areas,
and 12 (25%) were not speciﬁed.
An increase in the number of cases seen in travelers returning to
non-endemic areas may serve as a warning of potential outbreaks
in a particular region. Such was the case in 2001, when nine
patients with HAT (Table 2), were detected in Europe through
TropNetEurop.42–44 Prior to the early 1990s the number of tourists
infected with HAT was very low, although Tanzania is endemic for
the disease; the sudden rise in non-endemic cases was unusual. All
nine patients had traveled to Serengeti and Tarangire National
Parks in Tanzania, among other destinations. All patients suffered
from fever and most of the patients showed the trypanosomal
chancre. Microscopy of blood smears showed trypanosomes. Six
patients were treated with suramin during ﬁrst-stage HAT,
however three had multi-organ failure and showed signs of
cerebral involvement; these patients were treated with either
pentamidine or melarsoprol. Non-speciﬁc alternative treatments
were used, due to the unavailability of stage-speciﬁc medica-
tions.43 One patient, a 53-year-old Dutch woman died of the
disease.44,45 This patient was treated with a single dose of suramin
in South Africa and subsequently, melarsoprol treatment was
begun. She continued to suffer from headaches, fever, and
neurological deterioration. Five days after the last dose of
melarsoprol, the patient became paralyzed, went into a coma
and required artiﬁcial ventilation; she died approximately 4
months later.
Recently, a Dutch traveler was diagnosed with ﬁrst-stage T. b.
rhodesiense HAT.46 She was successfully treated in the Netherlandsand showed complete recovery at the 6-month follow-up.
Considering the past outbreak of 2001, this case may be cause
for concern.
Within a 1-week period in 2000, two unrelated patients
returning from Zambia and Tanzania were admitted to the Hospital
for Tropical Diseases in London.47,48 Both suffered from tsetse ﬂy
bites, diarrhea, vomiting, and fever. Upon admission, numerous
trypomastigotes were detected in microscopic examination of
blood smears. Treatment with suramin was uncomplicated and
both patients survived, but signiﬁcant effort went into obtaining
the drugs. Initially, the drug was not available at the hospital’s
pharmacy or from regional infectious or tropical disease units in
the UK, France, or Belgium. A small supply was obtained, after
delay, from the Liverpool School of Tropical Medicine, which
sufﬁced until a more complete course was provided by the Centers
for Disease Control and Prevention (CDC) in the USA.
A 30-year-old man was admitted to the Institute of Tropical
Medicine in Marseille, France after an insect bite while on vacation
in Rwanda left him with a severe headache and anorexia.49
Examination showed hepatosplenomegaly, lymphadenopathy,
purpura, and trypanosomes in the CSF. Treatment with predniso-
lone and melarsoprol was initiated, but twitching and encepha-
lopathy developed after the second course of melarsoprol.
Magnetic resonance imaging indicated lesions of the internal
capsules and excluded the possibility of post-treatment reactive
encephalopathy. Therefore, the treatment was continued, the
lesions progressively disappeared, and the patient’s prognosis was
positive, although the long-term outcome was not speciﬁed.
6. Discussion
Here, cases of T. b. rhodesiense and T. b. gambiense HAT in non-
endemic areas have been reviewed. HAT, in both clinical forms, is
rarely encountered in non-endemic countries; however, continued
surveillance and expertise in the diagnosis and management are
warranted due to the difﬁcult diagnosis and treatment decisions.9
Physicians should be aware of the disease and consider HAT in the
differential diagnosis if their patient is from or has traveled to an
endemic area. Non-endemic cases encountered over the past 20
years have been imported largely due to North Americans,
Australians, and Europeans traveling to endemic areas, primarily
for safari in game parks, but also military personnel training in
endemic areas. As the number of visitors to these game parks is
expected to increase, so too is the number of non-endemic cases.35
Cases are also observed among immigrants arriving from endemic
areas and in ex-patriots returning from postings abroad. Interest-
ingly, the epidemiology of HAT seen in non-endemic areas is the
opposite of the disease epidemiology seen in Africa. Of the
estimated 10 000–30 000 cases in endemic areas of Africa, more
than 95% of these cases are due to T. b. gambiense HAT.1 In the cases
presented here, approximately 30% of cases were due to T. b.
gambiense HAT and 70% were due to T. b. rhodesiense HAT. This is in
agreement with ﬁgures from the WHO, showing approximately 20
cases (40%) of T. b. gambiense and 30 (60%) of T. b. rhodesiense
diagnosed per year in non-endemic regions.9
According to our review, a common problem in non-endemic
regions is an initial misdiagnosis, particularly of T. b. gambiense
HAT. The chronic nature, characterized by non-speciﬁc clinical
signs and symptoms, and low parasitemia, may result in the
disease remaining undiagnosed and unrecognized for years.9,33 A
number of patients were initially symptomatically diagnosed and/
or presumptively treated for malaria,36,50,51 however as symptoms
persist there is a need to reassess the diagnosis. Patients with T. b.
gambiense HAT have been reported to have antibodies against T.
gondii, S. stercoralis,17 EBV,18 CMV,19 P. ﬁeldi, P. brasilianum, and B.
burgdorferi,20 further complicating diagnosis. This highlights the
Table 2
Reported non-endemic cases of Trypanosoma brucei rhodesiense human African trypanosomiasis
Age Sex Nationality Country of exposure Year Clinical features/symptoms Diagnosis Stage Treatment Outcome Ref.
ND M Swiss (tourist) Rwanda 1990 ‘‘Clinical signs of sleeping sickness’’ Blood, CSF II Melarsoprol Positive 35, 52
ND M Swiss (tourist) Rwanda 1990 ‘‘Clinical signs of sleeping sickness’’ Blood I Suramin Positive 35, 52
49 M American (tourist) Tanzania,
Kenya, Rwanda
1991 Fever, lesion, lymphadenopathy,
chills, sweat, anorexia, malaise, diarrhea
Blood I Pentamidine,
suramin
Positive 53
ND M French (solider) Rwanda 1994 Meningoencephalitis CSF II Melarsoprol Positive 54
ND M French (solider) Rwanda 1994 Major inﬂammatory syndrome Blood, medulla II Melarsoprol Positive 54
57 M Mexico (tourist) Kenya 1996 Fever, headache, lesion, hepatic
dysfunction, respiratory distress
Blood, lesion
exudate, CSF
II Pentamidine,
melarsoprol
Positive 55
30 M French (tourist) Rwanda 1997 Headache, weight loss, fever,
hepatosplenomegaly, lymphadenopathy
Blood, marrow, CSF II Melarsoprol Positive 49
41 M American (tourist) Tanzania 1999 Weakness, headache, fever, chills,
sweats, anorexia, lesion, lymphadenopathy
Blood, CSF II Suramin,
melarsoprol
Positive 56
54 F American (tourist) Tanzania 1999 fever, sweats, chills, myalgia, Blood I Suramin Positive 24
49 M American (tourist) Tanzania 1999 Malaise, drowsiness, insomnia, fever,
chills, sweats, headache, myalgia, lesion
Blood I Suramin Positive 24
47 F German (tourist) Zambia, Zimbabwe,
Tanzania
2000 Fever, insomnia, jaundice, lesion,
lymphadenopathy, mucosal hemorrhage,
splenomegaly, ascites
Blood, marrow I Suramin Positive 57
30 F Australian (tourist) East Africa 2000 Fever, rigors, headache, nausea, vomiting,
myalgia, splenomegaly
Blood I Pentamidine,
suramin
Positive 58
51 M British (tourist) Zambia 2000 Lesion, myalgia, diarrhea, fever, vomiting,
headache, rigors, sweats
Blood I Suramin Positive 47, 48
30 M British (tourist) Kenya, Tanzania 2000 Lesion, fever, diarrhea, vomiting Blood I Suramin Positive 43, 44
30 F Australian (tourist) Tanzania 2000 Fever, rigor, headache Blood I Pentamidine,
suramin
Positive 59
32 M ND (treated in Antwerp) Tanzania 2001 Fever, chancre, headache, jaundice,
hepatosplenomegaly
Blood I Suramin Positive 60
33 M Italian (tourist) Tanzania 2002 Fever, headache, nausea, vomiting, skin
lesion, lymphadenopathy
Blood I Pentamidine,
suramin
Positive 42, 43
30 M Italian (tourist) Tanzania 2002 Skin lesion, local edema, fever, mild jaundice,
multi-organ failure, hepatomegaly
Blood I Pentamidine Positive 42, 43
37 M American (tourist) Tanzania (Kenya,
Zimbabwe)
2002 Fever, lesion, headache, fatigue,
myalgia, vomiting, rash
Blood I Suramin Positive 26
7 patients American/ Canadian Tanzania 2002 ND ND ND ND ND 26
44 F British (tourist) Tanzania 2002 Lesion, fever ND II Pentamidine Positive 43
41 M Swedish (tourist) Tanzania 2002 Lesion, fever ND I Suramin Positive 43
68 M South African (tourist) Tanzania 2002 Fever, renal failure,
acidosis, jaundice
ND II Melarsoprol Positive 43
27 F Norwegian (researcher) Tanzania 2002 Lesion, fever ND I Suramin Positive 43
60 M Dutch (tourist) Tanzania 2002 Fever Blood I Suramin Positive 43, 44
55 F Dutch (tourist) Tanzania 2002 Lesion, fever, headache Blood I Suramin Positive 39, 40
53 F Dutch (tourist) Tanzania 2002 Lesion, fever, headache, intracerebral
manifestations, coma
Blood II Suramin,
melarsoprol
Death 35, 43–45
28 M Dutch (tourist) Kenya, Tanzania 2003 Fever, headache, myalgia, vertigo Blood I Suramin Positive 61
9 M British (tourist) Tanzania 2004 Lesion, fever, dry cough, vomiting Lesion aspirate I Suramin Positive 62
14 M British (tourist) Tanzania 2004 Abdominal pain, fever, lesion, dry cough,
vomiting, lymphadenopathy
Blood, lesion
aspirate
I Suramin Positive 62
26 M British (soldier) Malawi 2006 Insomnia, lethargy, vomiting, chancre,
lymphadenopathy, fever, rigors
Blood I Suramin Positive 63
25 F Australian (tourist) Malawi 2006 Fever, rigors, nausea, vomiting, diarrhea Blood I Suramin Positive 64
31 M Australian (tourist) Malawi 2006 Fever, myalgia, rigors, vomiting Blood I Suramin Positive 64
62 F American (tourist) Africa 2006 Fever, lesion, elevated IgM, rash Blood II Pentamidine,
suramin,
melarsoprol
Positive 54, 55
4 patients ND Canadian, British,
Australian
Malawi 2007 Thrombocytopenia, hallucinations Blood I Suramin ND 67
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S.J. Migchelsen et al. / International Journal of Infectious Diseases 15 (2011) e517–e524e522shortcomings of serological testing and emphasizes the need for
better and more sensitive means of detection in blood and CSF.71 In
this review it was found that diagnoses were based on symptoms
and microscopic detection of parasites in blood, lymph, or CSF.
Only one patient was conﬁrmed using CATT and in only three cases
was PCR used to conﬁrm the diagnosis,17,28,68 showing that
molecular or serological techniques have not replaced classic
parasitological techniques even in countries where equipment is
available3 (Tables 1 and 2).
A further problem complicating the management of patients is
the availability of drugs to treat HAT. Important to note is that,
thanks to the donations of Aventis and Bayer, all drugs for the
treatment of sleeping sickness are now readily available from the
WHO ofﬁce in Geneva (contact: SimarroP@who.int at WHO HTM/
NTD/IDM, Via Appia, Geneva, Switzerland), directly or via national
pharmacies. The CDC provides all pharmaceuticals to treat HAT in
the USA. As such, it maintains records of all HAT patients treated.
The disease is rare in the USA;72 only 14 cases were diagnosed and
treated between 1968 and 1985,73 and less than 10 were reported
during the two-decade period of this search.24,26,53,56,65,66 With
such a centralized system for the distribution of medication, any
increase in cases would hopefully become immediately apparent.
Many physicians still face difﬁculties acquiring suramin or
melarsoprol to treat their patients, highlighting the need for easy
access to these drugs.47 Due to the fact that HAT is classiﬁed as a
neglected tropical disease (NTD),74 there is little incentive for
pharmaceutical companies to invest in research, development, or
production of new anti-trypanosomal compounds, as those most in
need of the drug are not able to pay for treatment. In 2001 the
WHO, along with several international and non-governmental
organizations75 convinced Aventis, the pharmaceutical company
that manufactures pentamidine, melarsoprol, and eﬂornithine, to
guarantee a free production of these drugs.76 Storage and transport
of the drugs is to be overseen by Me´decins Sans Frontie`res (MSF).
Bayer has also agreed to provide free production of suramin and
continue production of nifurtimox. Similarly, the pharmaceutical
industry should be encouraged to develop new effective medica-
tions and provide them at an affordable cost. However, long-term
availability of all trypanocides, for both the endemic and non-
endemic countries, is still uncertain.26
Before embarking on travel to endemic areas, travelers should
be warned of the possible risks of HAT. General recommendations
to prevent tsetse ﬂy bites include wearing light-colored clothing
that fully covers the arms and legs,53 as well as the use of personal
insecticides. The most effective means for preventing trypanoso-
miasis, both in travelers and in those living in endemic areas, is the
control and reduction of vectors and reservoirs. Those advising and
treating travelers, whether primary care physicians or specialists
at a tropical center, should be vigilant for this disease. However,
since the vector is only present in sub-Saharan Africa, climate
change should not affect HAT as may be seen in other infectious
diseases such as Chikungunya by virus-carrying Aedes mosquitoes.
In 2001 the cluster of HAT cases in European travelers43 acted as
an alarm system for an increase in cases in Tanzania. By using
ProMED-mail and TropNetEurop as a surveillance tool for tropical
diseases the awareness of clinicians in both non-endemic and
endemic settings was increased. Information from this cluster of
cases was passed on to the Tanzanian Government to increase
vigilance in the affected region, which led to an increase in vector
control and surveillance programs.43 Currently TropNetEurop does
not report HAT cases and was only involved in 2001 due to the
unusually large outbreak. We recommend the expansion of
TropNetEurop to monitor HAT cases in Europe; in this manner,
potential outbreaks can be detected and a warning can be sent to
developing countries that might otherwise be unaware of the
situation.77
S.J. Migchelsen et al. / International Journal of Infectious Diseases 15 (2011) e517–e524 e523In conclusion, although there are relatively few cases of non-
endemic HAT, it is essential that knowledge and expertise of
diagnostics and treatment are made available in non-endemic
regions so that when cases occur, they can be rapidly and
effectively diagnosed and treated. This should include the use of
diagnostic algorithms since HAT is often not suspected in the ﬁrst
instance. We recommend the use of reference centers at tropical
departments in hospitals or institutes in non-endemic countries,
where diagnostic expertise, tests, and access to treatments are
available. Such institutions will hopefully be able to ensure
availability of drugs essential in the management of HAT under the
new drug distribution policy of the WHO.
Surveillance networks, such as ProMED-mail and TropNetEurop
should be maintained and expanded to ensure access to
institutional databases. Currently TropNetEurop is limited to
European collaborating centers and only reports on three imported
diseases: malaria, schistosomiasis, and dengue fever. We recom-
mend expanding the list of imported diseases that TropNetEurop
monitors and allowing public access to this database. Due to the
success of surveillance systems in Western countries, the
possibility of introducing similar ‘alarm’ systems for HAT in Africa
should be explored.
7. For further assistance
Assistance in diagnosis can be requested from the WHO
Collaborating Centre for Research and Training on Human African
Trypanosomiasis Diagnostics at the Institute of Tropical Medicine,
Antwerp (contact: Philippe Bu¨scher, pbuscher@itg.be).
All drugs are available from the WHO ofﬁce in Geneva and via
national pharmacies. Contacting this ofﬁce (Dr Pere Simarro and Dr
Jose Ramon Franco) enables the WHO to keep records of imported
HAT.
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